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Abstract 
Article History 
 
The  objective  of  the  present  study  was  to  develop  once-daily  tablet  of  Amisulpride,  a  
second generation  antipsychotic,  a  substituted  Benzamide.  The tablets were prepared by 
the wet granulation method.  Microcrystalline  Cellulose,  HydroxyPropylmethyl cellulose   
(HPMC),  Talc,  Magnesium Stearate,  Iso  Propyl  alcohol, Xanthan Gum, Kollidone Cross 
Pobidone, Aerosil, Avesil  101, 112,  102, Sodium  B i-car bonate,  Poly  vinylpyrollidone  K-
30,  Carbopol  with  varying  excipients  Six  bilayer  formulations AM1 –AM6 were  prepared 
by compressing  both Instant Release ( IR) and Sustained Release ( SR)  granules.  The 
granules were evaluated for bulk density, tapped density, compressibility, and Hausner ratio 
and moisture content. The tablets AM1– AM6 were evaluated. The granules showed 
satisfactory flow properties.  All  the  tablets  formulations  showed  acceptable  
Pharmacotechnical  properties  and  complied within  specifications  for  tested  parameters.  
The  results  of  dissolution  studies  indicated  that  the formulation    AM1 ,  AM2   and  AM3   
the  release  retardant use in combination  of SR  part  &  IR  part, AM1 (80:20), AM2 
(80:20)in combination of HPMC and poloxmer  188 and AM3   use is xanthane gum but 
process  not  fissile  and  dissolution  was  faster.  Formulation AM6 exhibited satisfactory 
drug release; amisulpride OD Bi- layer 400 mg tablets dissolved more than 90% in 24 hours.  
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Introduction 
Schizophrenia  is  the  most  common  form  of  severe  
mental  illness,  with  a  lifetime  risk  of developing  the  disease  
of  about  1% [1]. There is no cure available for schizophrenia.  
Traditional  or typical   antipsychotic  drugs  (neuroleptics),  
such  as  chlorpromazine  and  haloperidol,  appear  to  act 
centrally by blocking dopamine (D ) receptors in the brain. As a 
group, they relieve symptoms in at least 75% of patients during 
an acute attack [2]. Amisulpride is another atypical antipsychotic 
agent, structurally similar to sulpiride. It differs from other 
atypical in that it exhibits selective affinity for dopamine D2and 
D3receptors only. The  effectiveness  of  amisulpride  in  
improving  both  the  positive  and  negative symptoms of 
schizophrenia probably relates to its different effects on 
dopaminergic transmission at high and  low  doses [3,4] .  To  
characterize  the  role  of  the  5-HT7receptor  in  the  
antidepressant  effects  of amisulpride, a study Prepared 5-
HT7receptor knockout mice.  These results indicate that 5-HT7   
receptor   antagonism plays a major role in the antidepressant 
effects of amisulpride [5]. Amisulpride and its relative sulpiride 
have been shown to bind to and activate the GHB receptor at 
doses that are used for therapeutic purposes [6].Amisulpride 
400-1200mg/day was found to be as least as effective. At low 
doses amisulpride demonstrated a similar safety profile to 
placebo. At higher doses adverse events such as endocrine 
effects, agitation, insomnia and anxiety occurred at a similar r 
ate to that seen with other antipsychotics. It has no affinity for 
serotonergic alpha-adrenergic, H1 histaminergic or cholinergic 
receptors.  Amisulpride acts preferentially on presynaptic 
receptors increasing dopaminergic transmission at low doses 
[7]. There are two absorption peaks - one hour post-dose and a 
second 3-4 hour s after taking the tablet. The elimination half-
life is 12 hours. Absolute bioavailability is 48%.Amisulpride is 
weakly metabolized by the liver.  There are two inactive 
metabolites. The drug is mainly eliminated unchanged by the 
kidney. 50% of an IV dose is eliminated by the kidney of which 
90% is eliminated in the first 24 hours. Drug absorption is rapid, 
within 3-4 hours of oral administration and to improve patient 
compliance, a once-daily sustained-release formulation of 
Amisulpride is desirable. So, amisulpride bi-layer tablets were 
formulated comprising of I R part and SR part as layers.  
Because of their flexibility, hydrophilic polymer matrix systems 
are widely used  in  oral controlled  drug  delivery to  obtain  a 
desirable  drug  release  profile,  cost-effectiveness,  and Broad 
regulatory acceptance [8]. Hence, in the present work, 
hydrophilic matrix materials such as hydroxypropyl 
methylcellulose are used. Formulations AM1 to AM6 are 
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prepared by varying excipients. Microcrystalline Cellulose, 
Hydroxypropylmethylcellulose (H.P.M.C),Talc, Magnesium 
Stearate, Iso Propyl  alcohol, Xanthan Gum, Kollidone, Cross 
Pobidone ,Aerosil, Avesil  101,112,102,Sodium  Bi-carbonate, 
Poly vinylpyrollidone K- 30, Carbopol are used for formulation. 
 
Materials 
Amisulpride is purchased from (Anjan drug pvt.  Ltd  
Chennai)  Microcrystalline  Cellulose ( Colorcon  India  Ltd,  
Bombay),  Ferrous  Fed  Oxide  (Aqualon-USA) ,  H.P.M.C  ( 
ISP  Technologies, Bombay), Talc and Magnesium Stearate are 
gifted by (Mittal Polymer, Bombay). Iso Propyl alcohol (M/S 
National agencies, Bombay), Kollidone (Colorcon labs, 
Mumbai), Cross Povidone (ROHM Gmbh & co KG-thane 
Maharastra.),  Xanthenes  Gum  (Ranchem,  Avesil  
101,112,102  (Ranchem),  Sodium  Bi-carbonate  ( Ranbaxy  
Lab.Ltd.),  Poly  vinylpyrollidone  K- 30(ISP Technologies, 
Bombay), Aerosil, Carbopol were procured from (Degussa) [9].  
 
Release Rate and Dose Consideration 
As already mentioned, conventional dosage forms include 
solutions, Tablets, Tablets, emulsions, etc. These dosage 
forms can be considered to release their active ingredients into 
an absorption pool immediately. 
     Kr    Ka   Ke 
 
Dosage form                Absorption pool             Target area 
  Drug release         absorption                        elimination     
The absorption pool represents a solution of the drug at 
the site of absorption. 
Where    
Kr= First order rate constant for drug release. 
Ka=First order rate constant for drug absorption. 
Ke=First order rate constant for overall drug elimination. 
For immediate release dosage forms Kr >>> Ka or 
alternatively absorption of drug across a biological membrane 
is the rate-limiting step in delivery of the drug to its target area 
[10]. 
For non-immediate release dosage forms, Kr <<< Ka, that 
is, release of drug from the dosage form is the rate limiting 
step. This cause the above kinetics scheme to reduce to 
Dosage form                           Target area             
    Drug release                                 elimination             
Potential Advantages of Controlled Drug Therapy: All 
controlled release products share the common goal of 
improving drug therapy over that achieved with their non-
controlled counter parts. This improvement in drug therapy is 
represented by several potential advantages of the use of 
controlled release systems are [11,12] 
A) Avoid patient compliance problems. 
B) Reduction in total dose administered, thereby, 
i) Minimize or eliminate local side effects. 
ii) Minimize or eliminate systemic side effects. 
iii) Obtain less potentiation or reduction in drug activity 
with chronic use. 
iv) Minimize drug accumulation with chronic dosing. 
C) Improve efficiency in treatment. 
i) Cure or control condition more promptly. 
ii) Improve control of condition i.e. reduce fluctuation in 
drug level. 
iii) Improve bioavailability of some drugs. 
iv) Make use of special effects e.g. Sustained release 
aspirin for morning relief of   arthritis by dosing 
before bedtime. 
D) Economy. 
 
Drug Properties relevant to sustained release formulation 
The design of controlled-release delivery systems is 
subject to several variables of considerable importance. 
Among these are the route of drug delivery, the type of delivery 
system, the disease being treated, the patient, the length of 
therapy and the properties of the drug. Each of these variables 
are interrelated and this imposes certain constrains upon 
choices for the route of delivery, the design of the delivery 
system and the length of therapy. Properties of drugs are very 
important for designing a Sustained release dosage form. 
Mainly physicochemical and biological properties of the drug 
are most important [13]. 
 
1) Physicochemical Properties 
a) Aqueous solubility and pKa: -A drug to be absorbed it 
first must dissolve in the aqueous phase surrounding the site of 
administration and then partition into the absorbing membrane. 
Two of the most important physicochemical properties of a 
drug that influence its absorptive behaviour are its aqueous 
solubility and if it is a weak acid or base, its pKa. These 
properties play an influential role in the performance of 
controlled release systems [14]. 
The aqueous solubility of a drug influences its dissolution 
rate, which in turn establishes its concentration in solution and 
hence the driving force for diffusion across membrane. 
Dissolution rate is related to aqueous solubility as shown by 
the Noyes-Whitney equation that, under sink condition is 
Dc/dt=KDACs 
Where 
Dc/dt = Dissolution rate 
KD     = Dissolution rate constant 
A      = Total surface area of the drug particles. 
Cs       = Aqueous saturation solubility of the drug. 
b) Partition Coefficient:- Between time that a drug is 
administered and the time it is eliminated from the body, it 
must diffuse through a variety of biological membranes that act 
primarily as lipid like barriers [15]. A major criteria in evaluation 
of the ability of a drug to penetrate these lipid membranes is its 
apparent oil/water partition coefficient defined as  
K=C0/Cw 
Where 
C0 = Equilibrium concentration of all forms of the 
drug e.g. ionized and unionized in an organic phase at 
equilibrium 
Cw = Equilibrium concentration of all forms in aqueous 
phase. 
c) Drug stability:-One important factor for oral dosage 
forms is the loss of drug through acid hydrolysis and/or 
metabolism in the GI tract. Since a drug in the solid state 
undergoes degradation at a much slower rate than a drug in 
suspension or solution. It is possible to improve significantly 
the relative bioavailability of a drug that is unstable in GI tract 
by placing it in a slowly available controlled release form. For 
those drugs that are unstable in the stomach, the most 
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appropriate controlling unit would be one that releases its 
content only in the intestine. The reverse in the case for those 
drugs that are unstable in the environment of the intestine, the 
most appropriate controlling unit in this case would be one that 
releases its contents only in the stomach. So, drugs with 
significant stability problems in any particular area of the GI 
tract are less suitable for formulation into controlled release 
systems that deliver their content uniformly over the length of 
the GI tract. Controlled drug delivery systems may provide 
benefits for highly unstable drugs because the drug may be 
protected from enzymatic degradation by incorporation into a 
polymeric matrix [16]. 
d) Protein Binding:-There are some drugs which having 
tendency to bind with plasma proteins (eg. Albumin) and 
causes retention of the drug in the vascular space. The main 
force of attraction responsible for binding is van der Waal’s 
forces, hydrogen bonding and electrostatic forces. In general, 
charged compounds have a greater tendency to bind a protein 
than uncharged compounds, because of electrostatic effects. 
e) Molecular size and diffusivity:-Drugs in many 
controlled-release systems must diffuse through a rate 
controlling membrane or matrix. The ability of a drug to diffuse 
through membranes, it’s so called diffusivity (diffusion 
coefficient), is a function of its molecular size (or molecular 
weight).  
An important influence upon the value of the diffusivity, 
‘D’, in polymers is the molecular size (or molecular weight) of 
the diffusing species. For most polymers, it is possible to relate 
log D empirically to some function of molecular size as 
Log D = - Sv log V + KV = - SM logM + Km 
Where  
V = molecular volume. 
M = molecular weight. 
SV, SM, KV, Km = constant. 
 
2) Biological Properties 
1) Absorption:-The rate, extent and uniformity of 
absorption of a drug are important factors when considering 
formulating into a controlled-release system. Since the rate-
limiting step in drug delivery from a controlled-release system 
is its release from a dosage form, rather than absorption, a 
rapid rate of absorption of drug relative to its release is 
essential if the system is to be successfull [17]. In case of 
controlled release dosage form Kr <<<Ka. This becomes most 
critical in the case of oral administration. Assuming that the 
transit time of a drug through the absorption area of the GI 
tract is between 9 and 12 hrs, the maximum absorption half-life 
should be 3 to 4 hrs. This corresponds to a minimum 
absorption rate constant Ka of 0.17 to 0.23 hr-1 necessary for 
about 80 to 95 % absorption over a 9 to 12 hr transit time. 
For a drug with a very rapid rate of absorption (i.e. Ka>> 
0.23 hr-1), the above discussion implies that a first order 
release rate constant Kr< 0.17 hr-1 is likely to result in 
unacceptably poor bioavailability in many patients. Therefore, 
slowly absorbed drugs will be difficult to formulate into 
controlled release systems where the criterion that Kr<<< Ka 
must be met. 
2) Distribution: -The distribution of a drug into vascular 
and extra vascular spaces in the body is an important factor in 
its overall elimination kinetics. Two parameters that are used to 
describe the distribution characteristics of a drug are its 
apparent volume of distribution and the ratio of drug 
concentration in the tissue to that in plasma at the steady state, 
the so-called T/P ratio. The magnitude of the apparent volume 
of distribution can be used as a guide for additional studies and 
as a predictor for a drug-dosing regimen and hence the need 
to employ a controlled –release system. 
3) Metabolism: -Drugs that are significantly metabolized 
before absorption, either in the lumen or tissue of the intestine, 
can show decreased bioavailability from slower releasing 
dosage forms. Most intestinal wall enzyme systems are 
saturable. As the drug is released at a slower rate to these 
regions, less total drug is presented to the enzymatic process 
during a specific period allowing more complete conversion of 
drug to its metabolite. Formulation of these enzymatic ally 
susceptible compounds as prodrug is another viable solution 
[18]. 
4) Biological Half Life: -The half-life of Amisulpride is 
48%.The usual goal of an oral Sustained release product is to 
maintain therapeutic blood levels over an Sustained period. To 
this, drug must enter the circulation at approximately the same 
rate at which it is eliminated. The elimination rate is 
quantitatively described by the half-life. Each drug has its own 
characteristic elimination rate, which is the sum of all 
elimination processes including metabolism, urinary excretion 
and all other processes that permanently remove drug from 
blood stream. 
Therapeutic compounds with short half-life are excellent 
candidates for Extended-release preparations, since this can 
reduce dosage frequency. However, this is limited, in that 
drugs with very short biological half-life as it may require 
excessively large amounts of drug in each dosage unit to 
maintain Sustained effect, forcing the dosage form itself to 
become large. 
In general, drugs with half-life shorter than two hrs are 
poor candidates for Sustained release preparations. Drugs with 
long half-life, more than 8 hrs, are also generally not used in 
sustaining forms, since their effect is already extended [19]. 
5) Side Effects and Safety Considerations: -There are 
very few drugs whose specific therapeutic concentrations are 
known. Instead, a therapeutic concentration range is listed, 
with increasing toxic effects expected above this range and a 
falloff in desired therapeutic response observed below the 
range.  
The most widely used measure of the margin of safety 
of a drug is its therapeutic index (TI). 
 
 
 
Where  
TD50 = median toxic dose  
ED50 = median effective dose 
For very potent drugs, whose therapeutic concentration 
range is narrow, the value of TI is small. In general, larger the 
value of TI, the safer the drug. Drugs with very small value of 
TI usually are poor candidates for formulation into controlled-
release product. A drug is considered to be relatively safe if its 
TI value exceeds 10. 
6) Dose Size: -Since a controlled-release system is 
designed to alleviate repetitive dosing, it naturally will contain a 
TI  = TD 50 / ED50 
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greater amount of drug than a corresponding conventional 
dosage form. For those drugs requiring large conventional 
doses, the volume of the Sustained dose may be so large as to 
be impractical or unacceptable, depending on the route of 
administration. The same may be true for drugs that require a 
large release rate from the controlled-release system, e.g., 
drugs with shorter half-life. For oral route, the volume of the 
product is limited by patient acceptance [20]. 
 
Evaluation of Granules 
• Bulk density: -Bulk density is determined by 
measuring the volume of powder that has been passed 
through a screen, into a graduated cylinder. A quantity of 
100gr of sample from each for mula was introduced into a 
10ml measuring cylinder. After the initial volume was 
observed, the cylinder was allowed to tap 500, 750 and 1250 
taps and read corresponding values V500, V750 and V1250, 
to the nearest millilitre. Bulk density was calculated using in 
the following formula.   
Bulk density =W/V 
• Tapped density: -Tapped density is achieved by 
mechanically tapping a measuring cylinder containing a 
powder sample. After observing the initial volume, the 
cylinder is mechanically tapped, and volume readings are 
taken little further volume change is observed. The tapped 
density was calculated using in the following formula.   
Tapped density=W/V 
• Compressibility index: -The compressibility index of 
the granules was determined by measuring both the bulk 
volume and tapped volume of a powder. Compressibility 
index was calculated using in the following formula.   
Compressibility index=100XV0-Vf / V0 
• Hausner ratio: -Hausner Ratio was calculated using 
in the following formula [21]. 
Hausner Ratio=V0/Vf 
Characteristics of granules of Amisulpride OD Tablets 
formulation (table 1).
 
Table no 1- Characteristics of granules of Amisulpride OD Tablets formulation 
 
Evaluation of Tablets 
• Weight variation test:-To  study  weight  variation,  20 
tablets  for  each  single  dose preparations  presented  in  
individual containers were weighed using an electronic 
balance, and the test was performed according to the 
official method.  
• Thickness: -The thickness of the tablets was determined 
using a thickness gauge Five tablets from each batch were 
used (table 2) and average values were calculated.   
• Drug Content: -Five tablets were weighed individually, and 
the drug was extracted in water. The drug content was 
determined  by  weighing,  amount  of  powdered  granules  
(100  mg)  was  extracted  with  water   and  the solution  
was  filtered  through  0.45- membrane. The absorbance 
was measured with UV spectrometer after suitable dilution 
[22].   
• Hardness and Friability: -For each formulation, the 
hardness and friability of 6 tablets were determined using 
the hardness tester and the friabilator, respectively.   
• In-vitro Release Studies:-The  In-vitro dissolution  studies  
were  carried  out  using  USP  apparatus  type  II  at              
75  rpm. The dissolution medium consisted of                      
0.1N hydrochloric acid for the first 1 hour, then acetate              
buffer pH 3.0 to 4 hours and  phosphate buffer pH 7.4     
from 6 to 24 hours (900 mL), maintained at 37 C 0.5 C.               
The drug release at different time intervals was            
measured by UV- visible spectrophotometer [23]. 
 
S.N0. Formulation Bulk density 
g/ml 
Tapped density 
g/ml 
Compressibility index (%) Hausner 
ratio 
Moisture 
content (%) 
1 AM1 0.510 0.650 21.53 1.27 0.81% 
2 AM2 0.524 0.696 24.71 1.32 0.51% 
3 AM3 0.560 0.700 20.01 1.25 0.67% 
4 AM4 0.497 0.661 24.68 1.32 0.52% 
5 AM5 0.530 0.650 18.46 1.22 0.75% 
6 AM6 0.540 0.665 18.40 1.20 0.72 
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Table no. 2-Physico-chemical properties of Amisulpride OD Tablets formulation 
 
 
 
 
 
 
 
 
 
 
 
Conclusion 
The release profiles of Amisulpride OD Tablets were 
compared with our proposed release data. From this study it 
was concluded that Amisulpride for floating the tablets we did 
use the NaHCO3. So tablets retention time increase in GI fluid.  
We have to observe that we achieved our objective that, 
Amisulpride OD bi-layer 400 mg tablets dissolved more than 90 
% in 24 hours by the use of NaHCO3& above mentioned 
polymers. With the aim to check the Dissolution of the 
formulation the Drug formula for  AM6 was charged under 0.1 N 
HCl & Phosphate Buffer. The sample forAM6 achieves the 
acceptance criteria for Dissolved in 24 hours in dissolution 
medium.  
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S.No. Formulation Weight 
variation 
Content 
uniformity 
D.T Assay (%) 
1 AM1 750± 5% 101 (2.5) 18 hour 30 sec 102.1 
2 AM2 860 ± 5% 99.84(2.1) 19hour 30 sec. 97.83 
3 AM3 860± 5% 100.1(2.5) 21 hour 45 sec 96.15 
4 AM4 990 ± 5% 97.5(3.5) 22 hour 10 sec 104.09 
5 AM5 990 ± 5% 98.99(3.1) 23 hour 20sec 101.13 
6 AM6 990 ±5% 99.10(2.9) 23 hour 40sec  101.11 
